GSK, Shingles and Respiratory syncytial virus vaccine
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with Shingrix (Zoster Vaccine).
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial showed that co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ produced a non-inferior immune response and was well tolerated.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody concentrations (immune response to Shingrix) and RSV-A and RSV-B neutralization titers increased from pre- to post-vaccination.
GSK shingles vaccine now available in Malaysia
A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine,
GSK Shingles Vaccine in Malaysia: Here’s What You Need to Know
GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side effects, for whom and where to get it.
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
Joplin Globe2d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Please see full Prescribing Information for AREXVY. About SHINGRIX (Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of ...
dermatologyadvisor6d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50 Years or Older
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
American States Ranked by the Highest and Lowest Vaccination Rates
Rhode Island has the highest vaccination rate across the country, while Mississippi was found to have the lowest, a new study ...
bernama3d
Shingles May Cause Long-Term Pain In Older People – Expert
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
Hosted on MSN15d
Mpox vs. Chickenpox: What Are the Differences?
While the chickenpox vaccine can provide lifelong protection against chickenpox, another two-dose vaccine called Shingrix (recombinant zoster vaccine) is recommended for adults age 50 and over ...
Parade on MSN4d
Want To Lower Your Dementia Risk? Don’t Skip This Vaccine
It’s easy to see how vaccines for health conditions that don’t make headlines as much as COVID or the flu (which everyone ...
Renal & Urology News7d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50+
Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...
Gazeta.pl on MSN22h
A Vaccine Against an Infectious Disease Protects Against Dementia? "Intriguing"
The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...